GlassScriptPhysician profile
Reza Farhangfar
NPI 1184709297
$4,907.77
in general payments reported to CMS, 2019-2025
30 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $565 · 2021: $866 · 2022: $563 · 2023: $556 · 2024: $359 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,887 · Education: $94.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,886.91 |
| Education | $94.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,570.19 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,048.71 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.67 | 2019-2023 | Ofev |
| Jazz Pharmaceuticals INC. | $225.37 | 2019-2021 | |
| Mylan Specialty L.P. | $220.30 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $207.10 | 2019-2021 | |
| Insmed, INC. | $162.50 | 2019-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $154.29 | 2019-2025 | Dupixent |
| Philips North America LLC | $111.05 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Verona Pharma, INC. | $105.59 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $96.09 | 2020-2024 | Wakix |
| Teva Pharmaceuticals USA, INC. | $86.98 | 2019-2023 | |
| Genzyme Corporation | $78.22 | 2019-2025 | |
| Grifols USA, LLC | $62.10 | 2021-2025 | Prolastin-C Liquid |
| Amgen INC. | $61.93 | 2022-2023 | Tezspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57.37 | 2023 | |
| Mallinckrodt Hospital Products INC. | $57.18 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $49.70 | 2021-2022 | |
| Axsome Therapeutics, INC. | $47.41 | 2023 | Sunosi |
| United Therapeutics Corporation | $34.79 | 2021-2023 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $34.42 | 2023-2024 | Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $26.47 | 2020-2021 | |
| Advanced Respiratory, INC | $19.84 | 2021 | |
| Viatris Specialty LLC | $18.66 | 2025 | Yupelri |
| Pulmonx Corporation | $16.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.95 | 2019 | |
| Shire North American Group INC | $14.23 | 2019 | |
| Merck Sharp & Dohme LLC | $12.67 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.47 | 2019 | |
| Circassia INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Farhangfar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.